Preclinical efficacy of a prototype dna vaccine: Enhanced protection against antigenic drift in influenza virus

Nature Medicine

Volumn 1, Issue 6, 1995, Pages 583-587

  Donnelly, John J ^a   Friedman, Arthur ^a   Martinez, Douglas ^a   Montgomery, Donna L ^a   Shiver, John W ^a   Motzel, Sherri L ^b   Ulmer, Jeffrey B ^a   Liu, Margaret A ^a  

^a Departments of Virus and Cell Biology ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; INFLUENZA VIRUS; INTRAMUSCULAR DRUG ADMINISTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

ANIMAL; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; COMPARATIVE STUDY; DNA, RECOMBINANT; FERRETS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS, VIRAL; HUMAN; INFLUENZA; INFLUENZA A VIRUS, HUMAN; INFLUENZA VACCINE; MALE; NUCLEOPROTEINS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 0029051152     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0695-583     Document Type: Article

References (37)

1. Chakraverty, M. et al Update: Influenza activity-United States and worldwide, and composition of the 1993-94 influenza vaccine. Morbid. Mortal Weekly Rep. 42, 177-180(1993).
2. Shu, L.L., Bean, W.J. & Webster, R.G. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 67, 2723-2729 (1993).
3. Ito, T. et al Evolutionary analysis of the influenza A virus M gene with comparison of the Ml and M2 proteins. J. Virol 65, 5491-5498 (1991).
4. Rocha, E.P. etal Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J. gen. Virol. 74, 2513-2518, (1993).
5. Nichol, K.L. etal The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New Engl. J. Med. 331, 778-784 (1994).
6. Clements, M.L. etal. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J. clin. Microbiol 30, 655-662 (1992).
7. Murphy, B.R. et al Evaluation of three strains of influenza A virus in humans and in owl, cebus, and squirrel monkeys. Infect. Immun. 28, 688-691 (1980).
8. Berendt, R.F. & Scott, G.H. Evaluation of commercially prepared vaccines for experimentally induced type AJNew JerseyJ76 influenza virus infections in mice and squirrel monkeys. J. infect Dis. 136, S712-S717 (1977).
9. Berendt, R.F. & Hall, W.C. Reaction of squirrel monkeys to intratracheal inoculation with influenza AJNew JerseyJ76 (swine) virus. Infect. Immun. 16, 476-479 (1977).
10. Yetter, R.A., Barber, W.H, & Small, P.A. Heterotypic immunity to influenza in ferrets. Infect. Immun. 29, 650-653 (1980).
11. Smith, H. & Sweet, C. Lessons for human influenza from pathogenicity studies with ferrets. Rev. infect. Dis. 10, 56-75 (1988).
12. Sears, S.D. et al Comparison of live, attenuated H1N1 and H3N2 cold- adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J. infect. Dis. 158, 1209-1219 (1988).
13. Couch, R.B. etal. Influenza: Its control in persons and populations. J. infect. Dis. 153, 431-440 (1986).
14. Murphy, B.R. et al Temperature-sensitive mutants of influenza virus. III. Further characterization of the β-l[E] influenza A recombinant (H3N2) virus in man. J. infect. Dis. 128, 479-487 (1973).
15. Katz, J.M. & Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. infect. Dis. 160, 191-198 (1989).
16. Newman, R.S, et al. Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule. Vaccine 11, 400-406 (1993).
17. Sawyer, L.S.W. etal Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. I. Virol 68, 1342-1349 (1994).
18. Mahr, A. & Payne, L.G. Vaccinia recombinants as vaccine vectors. Immunobiology 184, 126-146 (1992).
19. Graham, F.L. & Prevec, L. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20, 363-390 (1992).
20. Asano, Y. etal. Experience and reason: 20-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524-526 (1994).
21. Wolff, J.A. etal Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. molec. Genet. 1, 363-369 (1992).
22. Manthorpe, M. et al. Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4, 419-431 (1993).
23. Clements, M.L. etal Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza BJAnn ArborJ1J86 reassortant virus vaccine in adult volunteers. J. infect. Dis. 161, 869-877 (1990).
24. Powers, D.C. et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. din. Microbiol. 29, 498-505 (1991).
25. Ulmer, J.B. et al. Heterologous protective immunity to influenza A by intramuscular injection of DNA encoding a conserved viral protein. Science 259, 1745-1749 (1993).
26. Montgomery, D.L. et al Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol. 12, 777-784 (1993).
27. Wang, B. et al Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 90, 4156-4160(1993).
28. Cox, Zamb, T.J. & Babiuk, L.A. Bovine Herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA. J. Virol 67, 5664-5667 (1993).
29. Xiang, Z.Q. et al Vaccination with a plasmid carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199, 132-140 (1994).
30. Both, G.W., Sleigh, M.J., Cox, N.J. & Kendal, A.P. Antigenic drift in influenza virus H3 haemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol 48, 52-60 (1983).
31. Yang, Y.P. etal. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. natn. Acad. Sci.U.S.A. 91, 4407-4411 (1994).
32. Cooney, E.L. et al Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567-572(1991).
33. Redfield, R.R. et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. New Engl. J. Med. 316, 673-676 (1987).
34. Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
35. Kuwano, K. et al. Active immunization against virus infections due to antigenic drift by induction of cross-reactive cytotoxic T lymphocytes. J. exp. Med. 169, 1361-71 (1989).
36. Mbawuike, I.N. et al. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1JHA2 influenza virus protein. Vaccine 12, 1431-48 (1994).
37. Fries, L.F. et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J. infect. Dis. 167, 593-601.